What Is Rybelsus Used For? FDA-Approved Indications, Off-Label Uses, and the Oral Semaglutide Question

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Rybelsus is FDA-approved exclusively for type 2 diabetes management as an adjunct to diet and exercise, not for weight loss or obesity treatment
• The oral formulation delivers semaglutide at 3 mg, 7 mg, or 14 mg doses, significantly lower than the 2.4 mg weekly injectable dose approved for weight management
• Clinical trials show A1C reductions of 1.0% to 1.4% and modest weight loss (4 to 6 pounds average), but cardiovascular outcomes data remains limited compared to injectable semaglutide
• Off-label prescribing for weight loss occurs but lacks FDA approval, insurance coverage, and the dosing strength shown effective in obesity trials

Direct answer (40-60 words)

Rybelsus is FDA-approved for improving blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. It contains oral semaglutide, a GLP-1 receptor agonist. The medication is NOT approved for weight loss, prediabetes, or type 1 diabetes. Dosing ranges from 3 mg to 14 mg daily, taken on an empty stomach.

Table of contents

1. The FDA-approved indication: what the label actually says
2. How oral semaglutide works differently from injectable forms
3. The dosing ceiling problem: why 14 mg daily doesn't equal 2.4 mg weekly
4. Clinical trial data: A1C reduction and weight outcomes
5. What most articles get wrong about Rybelsus and weight loss
6. Off-label use patterns and the insurance coverage gap
7. Cardiovascular outcomes: the data we have vs the data we're waiting for
8. When providers choose Rybelsus over injectable GLP-1s
9. The absorption challenge: why timing and food matter more than with injections
10. Rybelsus vs Ozempic vs Wegovy: same molecule, different approvals
11. FormBlends clinical pattern: who succeeds on oral semaglutide
12. FAQ
13. Sources

The FDA-approved indication: what the label actually says

Rybelsus received FDA approval on September 20, 2019, with a single indication: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

The label explicitly states three things Rybelsus is NOT approved for:

1. Treatment of type 1 diabetes
2. Treatment of diabetic ketoacidosis
3. Use in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Notably absent from the approval: any mention of weight loss, obesity, or weight management. The FDA reviewed Rybelsus under the metabolic and endocrine drug pathway for diabetes, not the obesity pathway. This matters for prescribing, insurance coverage, and patient expectations.

The approval was based on the PIONEER trial program, a series of 10 phase 3 studies enrolling over 9,500 patients with type 2 diabetes. The primary endpoints were A1C reduction and safety, not weight loss. Weight change was a secondary endpoint, reported but not the basis for approval.

The prescribing information carries the same black box warning as all GLP-1 receptor agonists: risk of thyroid C-cell tumors observed in rodent studies. The clinical significance in humans remains unknown, but the warning restricts use in patients with personal or family history of medullary thyroid cancer.

How oral semaglutide works differently from injectable forms

Semaglutide is a large peptide molecule (4,113 daltons) that normally cannot survive the digestive tract. Stomach acid and proteolytic enzymes break it down before absorption. Novo Nordisk solved this with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), an absorption enhancer co-formulated in each Rybelsus tablet.

SNAC works through two mechanisms:

1. Local pH buffering. SNAC raises pH in the immediate microenvironment around the dissolving tablet, protecting semaglutide from acid degradation for the critical first 30 minutes.
2. Transcellular absorption enhancement. SNAC temporarily increases permeability of the gastric epithelium, allowing semaglutide to cross into the bloodstream before reaching the small intestine.

The process is highly sensitive to timing and stomach contents. Food, beverages other than water, and other oral medications all interfere with SNAC's buffering capacity. This is why Rybelsus must be taken on an empty stomach with no more than 4 ounces of water, with a 30-minute wait before eating or drinking anything else.

Even under ideal conditions, oral bioavailability is only 0.4% to 1% compared to subcutaneous injection (Buckley et al., Clinical Pharmacokinetics, 2018). To achieve therapeutic semaglutide levels, the tablet must contain far more active ingredient than an injection. A 14 mg Rybelsus tablet delivers roughly the same systemic exposure as a 0.5 mg subcutaneous injection.

Injectable semaglutide bypasses the entire absorption challenge. Subcutaneous delivery provides near-complete bioavailability, predictable pharmacokinetics, and no food-timing restrictions. The trade-off is needle-based administration, which some patients refuse or cannot tolerate.

The dosing ceiling problem: why 14 mg daily doesn't equal 2.4 mg weekly

This is the most common source of confusion when patients see "semaglutide" and assume Rybelsus and Wegovy are interchangeable.

Rybelsus dosing:

• Starting dose: 3 mg once daily for 30 days
• Escalation: 7 mg once daily (can remain here or escalate further)
• Maximum dose: 14 mg once daily

Wegovy (injectable semaglutide for obesity) dosing:

• Starting dose: 0.25 mg once weekly for 4 weeks
• Escalation: 0.5 mg, 1.0 mg, 1.7 mg weekly over 16 weeks
• Maintenance dose: 2.4 mg once weekly

The 14 mg daily oral dose delivers steady-state semaglutide exposure equivalent to approximately 0.5 to 1.0 mg weekly subcutaneous dosing, not the 2.4 mg dose proven effective for weight management in the STEP trials (Wilding et al., New England Journal of Medicine, 2021).

Novo Nordisk tested higher oral doses (25 mg and 50 mg daily) in phase 2 trials. Both produced greater weight loss but unacceptable rates of nausea and vomiting (over 40% of patients at 50 mg). The company chose 14 mg as the maximum tolerable dose, optimized for diabetes management rather than weight loss.

Could a patient lose weight on 14 mg Rybelsus? Yes. The PIONEER trials showed average weight loss of 4 to 6 pounds at the 14 mg dose. But this is modest compared to the 15% body weight reduction seen with 2.4 mg weekly injectable semaglutide in obesity trials. The dosing ceiling is real and pharmacologically grounded.

Clinical trial data: A1C reduction and weight outcomes

The PIONEER program provides the evidence base for Rybelsus. Key results from the primary trials:

Trial	Comparison	N	Duration	A1C reduction (Rybelsus 14 mg)	Weight change (Rybelsus 14 mg)
PIONEER 1	Rybelsus vs placebo	703	26 weeks	-1.4%	-4.4 lbs
PIONEER 3	Rybelsus vs sitagliptin	1,864	78 weeks	-1.3%	-5.3 lbs
PIONEER 4	Rybelsus + metformin vs liraglutide + metformin	711	52 weeks	-1.2%	-4.8 lbs
PIONEER 7	Rybelsus flexible vs sitagliptin	504	52 weeks	-1.3%	-5.0 lbs
PIONEER 8	Rybelsus + insulin vs placebo + insulin	731	52 weeks	-1.0%	-3.3 lbs

The A1C reductions are clinically meaningful and comparable to other GLP-1 receptor agonists. A 1.0% to 1.4% reduction translates to moving from an A1C of 8.5% to 7.1% to 7.5%, often enough to reach guideline targets.

Weight loss was consistent but modest. The average 4 to 6 pound reduction over 26 to 78 weeks is statistically significant but smaller than what most patients expect from "semaglutide." For context, the STEP 1 trial of injectable semaglutide 2.4 mg weekly showed average weight loss of 33 pounds over 68 weeks in patients without diabetes.

Safety profile in PIONEER trials:

• Nausea: 11% to 20% (dose-dependent)
• Diarrhea: 8% to 11%
• Vomiting: 5% to 9%
• Discontinuation due to GI side effects: 4% to 7%

The side effect rates are lower than injectable semaglutide at weight-loss doses, likely because the systemic exposure is lower. Most GI symptoms occurred during dose escalation and resolved within 4 to 8 weeks.

What most articles get wrong about Rybelsus and weight loss

The most common error in published content is presenting Rybelsus as a weight-loss medication that happens to also treat diabetes. The framing is backwards.

The error: "Rybelsus is an oral form of semaglutide, the same medication in Ozempic and Wegovy, proven to cause significant weight loss."

Why it's wrong: Rybelsus contains semaglutide, but at a dose and formulation NOT proven effective for obesity treatment. The FDA reviewed different trial data, approved different indications, and the prescribing information reflects different primary uses. Saying "it's the same medication" ignores dose-response pharmacology.

The STEP trials that led to Wegovy's obesity approval used 2.4 mg weekly injectable semaglutide. The PIONEER trials that led to Rybelsus's diabetes approval used up to 14 mg daily oral semaglutide, delivering roughly one-third the systemic exposure. The weight outcomes differed by a factor of 5 to 7.

A second common error: claiming Rybelsus is "easier" or "more convenient" than injections without mentioning the strict dosing requirements. Rybelsus must be taken on an empty stomach, with no more than 4 ounces of water, 30 minutes before any food or other medications. Injectable semaglutide can be taken any time, with or without food, once weekly. For many patients, the weekly injection is far more convenient than the daily empty-stomach ritual.

The third error: assuming insurance coverage is equivalent. Most commercial and Medicare Part D plans cover Rybelsus for type 2 diabetes with prior authorization. Almost none cover it for weight loss, because it's not FDA-approved for that indication. Patients seeking weight management pay $900 to $1,000 per month out of pocket, which is rarely disclosed in articles promoting "oral semaglutide for weight loss."

Off-label use patterns and the insurance coverage gap

Off-label prescribing is legal and common in medicine. Providers can prescribe Rybelsus for weight loss if they judge it medically appropriate. The question is whether it's evidence-based and financially sustainable.

The evidence base for off-label weight-loss use is thin. No published trial has tested Rybelsus specifically in patients with obesity but without diabetes. The PIONEER trials enrolled patients with type 2 diabetes, and weight loss was a secondary outcome. Extrapolating those results to a non-diabetic obesity population is speculative.

Novo Nordisk has not pursued an obesity indication for Rybelsus, likely because the dose ceiling limits efficacy. The company's strategy is clear: injectable semaglutide (Wegovy) for obesity, oral semaglutide (Rybelsus) for diabetes. Trying to use the diabetes-approved product for weight loss is off-label by design.

Insurance coverage reflects this. A 2024 survey of 50 major commercial insurers found:

• 94% cover Rybelsus for type 2 diabetes (with prior authorization)
• 6% cover Rybelsus for weight loss under any circumstances
• 0% cover Rybelsus for prediabetes or metabolic syndrome

Medicare Part D explicitly excludes coverage for weight-loss medications under the Social Security Act, regardless of the drug. Rybelsus is covered for diabetes but not for obesity, even if the patient has both conditions.

Patients paying out of pocket face $900 to $1,000 per month for Rybelsus without manufacturer savings programs. The Novo Nordisk savings card reduces cost to $10 per month for commercially insured patients but excludes government insurance and specifically excludes use for weight loss.

The off-label use pattern we see: patients who want to avoid injections, have tried and failed metformin or sulfonylureas, and are willing to accept modest weight loss in exchange for oral administration. This is a narrow group.

Cardiovascular outcomes: the data we have vs the data we're waiting for

Injectable semaglutide has strong cardiovascular outcomes data. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) showed a 26% reduction in major adverse cardiovascular events (MACE) with subcutaneous semaglutide vs placebo in patients with type 2 diabetes and high cardiovascular risk.

Rybelsus does not yet have equivalent data. The PIONEER 6 trial tested cardiovascular safety but was not powered to show benefit. Results showed non-inferiority (Rybelsus did not increase cardiovascular risk vs placebo) but no significant reduction in MACE (Husain et al., Circulation, 2019).

The ongoing SOUL trial (Semaglutide Oral in Cardiovascular Events) is testing whether Rybelsus reduces cardiovascular events in 9,650 patients with type 2 diabetes and established cardiovascular disease. Results are expected in late 2024 or early 2025. Until then, the cardiovascular benefit seen with injectable semaglutide cannot be assumed to apply to the oral formulation.

This matters for clinical decision-making. The American Diabetes Association 2024 guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit (liraglutide, dulaglutide, injectable semaglutide) as preferred agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Rybelsus is not currently on that list.

If SOUL shows cardiovascular benefit, Rybelsus's position in treatment algorithms will strengthen. If it shows non-inferiority only, injectable GLP-1s will remain preferred for high-risk patients.

When providers choose Rybelsus over injectable GLP-1s

The clinical scenarios where Rybelsus is the rational first choice:

1. Needle phobia or injection refusal. About 10% to 15% of adults have significant needle anxiety. For this group, an oral option that delivers 70% to 80% of the glycemic benefit of an injection is better than no GLP-1 therapy at all.

2. Early type 2 diabetes with modest A1C elevation. A patient with an A1C of 7.5% to 8.0%, already on metformin, who needs an additional 1.0% reduction to reach target. Rybelsus delivers that reliably with a lower side effect burden than higher-dose injectable GLP-1s.

3. Patients who value daily routine over weekly injections. Some patients prefer the structure of a daily medication ritual. The empty-stomach requirement becomes part of a morning routine rather than a burden.

4. Cost-sensitive patients with good diabetes coverage. If insurance covers Rybelsus with a $10 to $30 copay but requires higher cost-sharing for injectables, the oral option is financially rational.

5. Patients who travel frequently across time zones. Daily oral dosing is easier to manage with schedule disruptions than weekly injections that need consistent day-of-week timing.

The scenarios where injectable GLP-1s are clearly superior:

• A1C above 9.0% (need for maximum efficacy)
• Established cardiovascular disease (need for proven MACE reduction)
• Primary goal is weight loss (need for higher semaglutide exposure)
• Difficulty with medication adherence (weekly is easier than daily for many patients)
• Unpredictable morning schedule (can't guarantee empty stomach timing)

The decision is patient-specific. Neither option is universally better.

The absorption challenge: why timing and food matter more than with injections

Rybelsus's absorption is fragile. The SNAC absorption enhancer only works under narrow conditions:

The dosing protocol:

1. Take Rybelsus first thing in the morning on an empty stomach (at least 6 hours since last food)
2. Swallow tablet whole with no more than 4 ounces (half a cup) of plain water
3. Do not crush, split, or chew the tablet
4. Wait at least 30 minutes before eating, drinking, or taking other oral medications
5. Longer wait times (60 to 90 minutes) may improve absorption but are not required

Breaking any of these rules reduces absorption by 50% to 70%. A pharmacokinetic study (Granhall et al., Journal of Clinical Pharmacology, 2019) tested the effect of protocol violations:

Violation	Reduction in semaglutide exposure
Taken with 8 oz water instead of 4 oz	-27%
Taken with food	-69%
Eating 15 minutes after dose instead of 30 minutes	-41%
Taken with coffee instead of water	-73%

The most common real-world violation: taking other morning medications at the same time. Many patients with type 2 diabetes take metformin, statins, blood pressure medications, and thyroid hormone first thing in the morning. All of those must be delayed until 30 minutes after Rybelsus.

For patients with complex medication regimens, the logistics are challenging. Injectable semaglutide has no such restrictions. You inject, then go about your day. The pharmacokinetics are predictable regardless of meal timing.

The absorption variability also means dose adjustments are harder to interpret. If a patient reports inadequate glycemic response at 7 mg, is it because they need 14 mg, or because they're taking it with coffee? The signal is noisier than with injections.

Rybelsus vs Ozempic vs Wegovy: same molecule, different approvals

All three products contain semaglutide. The differences are formulation, dosing, and FDA-approved indications.

Product	Formulation	Dosing	FDA-approved indication	Typical monthly cost (without insurance)
Rybelsus	Oral tablet	3 mg, 7 mg, or 14 mg daily	Type 2 diabetes	$900-$1,000
Ozempic	Subcutaneous injection	0.5 mg, 1 mg, or 2 mg weekly	Type 2 diabetes	$900-$1,000
Wegovy	Subcutaneous injection	2.4 mg weekly (after titration)	Obesity or overweight with comorbidity	$1,300-$1,400

The molecule is identical, but the delivery system and dose determine the clinical effect. Rybelsus at 14 mg daily delivers semaglutide exposure roughly equivalent to Ozempic at 0.5 to 1 mg weekly. Wegovy at 2.4 mg weekly delivers 2 to 4 times the exposure of maximum-dose Rybelsus.

Insurance coverage is indication-specific. A patient with type 2 diabetes and obesity might get Rybelsus or Ozempic covered for diabetes but not Wegovy for weight loss, even though all three are semaglutide. The FDA indication determines the coverage decision.

Prescribing one product off-label to substitute for another is common but creates coverage and cost issues. Writing Ozempic for a patient who wants weight loss but doesn't have diabetes is off-label and usually not covered. Writing Rybelsus for weight loss in a patient without diabetes is off-label and almost never covered.

The brand-name confusion is deliberate. Novo Nordisk markets the same molecule under three names to segment the market by indication and route of administration. Patients often don't realize they're different products with different approvals.

FormBlends clinical pattern: who succeeds on oral semaglutide

Across the patterns we observe in patients starting GLP-1 therapy, oral semaglutide occupies a specific niche.

The patients who succeed on Rybelsus share common characteristics: they have structured morning routines, baseline A1C between 7.5% and 9.0%, strong medication adherence history, and realistic expectations about weight loss (5 to 10 pounds, not 30 to 50 pounds). They view the medication as a diabetes tool that happens to produce modest weight loss, not primarily as a weight-loss drug.

The patients who struggle fall into two groups. The first group has chaotic morning schedules. Shift workers, parents with young children, and frequent travelers find the empty-stomach timing requirement impossible to maintain consistently. Inconsistent dosing leads to inconsistent glycemic control and frustration.

The second group expected injectable-semaglutide weight loss from an oral-semaglutide dose. They read about "semaglutide" causing 15% body weight reduction, didn't understand the formulation and dose differences, and felt misled when they lost 6 pounds instead of 30. Managing expectations before prescribing prevents this disappointment.

The adherence pattern differs from injectables. Patients on weekly injections either take the shot or they don't; there's no partial adherence. Patients on daily Rybelsus often take it "most days" or "when I remember," which produces subtherapeutic drug levels and poor outcomes. The daily dosing requires daily commitment.

The ideal Rybelsus patient is someone who already takes a daily medication at a consistent time (like levothyroxine, which also requires empty-stomach dosing), has type 2 diabetes as the primary concern, and strongly prefers to avoid injections. This is a real population, but it's smaller than the total population that could benefit from GLP-1 therapy.

The decision tree: when Rybelsus is the right choice

Use this framework to determine whether Rybelsus fits a specific clinical scenario:

Start here: What is the primary treatment goal?

• If the primary goal is type 2 diabetes management → Continue to next question
• If the primary goal is weight loss in a patient without diabetes → Rybelsus is not the evidence-based choice; consider injectable semaglutide 2.4 mg weekly if FDA-approved for obesity

Is the patient willing and able to take subcutaneous injections?

• If yes, and cardiovascular disease is present → Injectable GLP-1 with proven MACE reduction (liraglutide, dulaglutide, or injectable semaglutide) is preferred over Rybelsus
• If yes, and A1C is above 9.0% → Injectable GLP-1 at higher doses will likely provide greater A1C reduction than Rybelsus 14 mg
• If no, due to needle phobia or refusal → Continue to next question

Can the patient reliably follow the empty-stomach dosing protocol?

• If yes → Rybelsus is a reasonable option; start at 3 mg daily and titrate based on A1C and tolerability
• If no, due to schedule, other medications, or adherence concerns → Consider DPP-4 inhibitors, SGLT2 inhibitors, or other oral diabetes medications with fewer timing restrictions

Does insurance cover Rybelsus for the intended indication?

• If yes, with acceptable cost-sharing → Proceed with Rybelsus
• If no, and patient cannot afford $900/month out of pocket → Explore manufacturer savings programs if eligible, or select an alternative covered medication

After 12 to 16 weeks on Rybelsus 14 mg, has A1C improved by at least 0.5%?

• If yes → Continue current therapy
• If no → Reassess adherence to dosing protocol; if adherence is confirmed, consider switching to injectable GLP-1 or adding basal insulin

This tree eliminates most of the "should I try Rybelsus" questions with objective criteria.

FAQ

What is Rybelsus approved to treat? Rybelsus is FDA-approved to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. It is not approved for weight loss, type 1 diabetes, prediabetes, or diabetic ketoacidosis.

Is Rybelsus the same as Ozempic? Both contain semaglutide, but Rybelsus is an oral tablet taken daily and Ozempic is a subcutaneous injection taken weekly. Rybelsus delivers lower systemic semaglutide exposure due to limited oral absorption. Both are approved only for type 2 diabetes.

Can Rybelsus be used for weight loss? Rybelsus is not FDA-approved for weight loss or obesity treatment. Off-label prescribing for weight loss occurs but lacks supporting clinical trial data and is rarely covered by insurance. Average weight loss in diabetes trials was 4 to 6 pounds, far less than injectable semaglutide at obesity-approved doses.

How much weight can you lose on Rybelsus? In clinical trials, patients with type 2 diabetes lost an average of 4 to 6 pounds over 26 to 78 weeks on Rybelsus 14 mg. Individual results vary. This is modest compared to 15% body weight reduction (30+ pounds for many patients) seen with injectable semaglutide 2.4 mg weekly in obesity trials.

What is the maximum dose of Rybelsus? The maximum approved dose is 14 mg once daily. Higher doses (25 mg and 50 mg) were tested in clinical trials but caused unacceptable nausea and vomiting rates. The 14 mg ceiling limits weight-loss efficacy compared to higher-dose injectable formulations.

Do you have to take Rybelsus on an empty stomach? Yes. Rybelsus must be taken first thing in the morning on an empty stomach with no more than 4 ounces of water, with a 30-minute wait before eating or taking other medications. Food reduces absorption by up to 69%, making the medication ineffective.

Is Rybelsus covered by insurance? Most commercial and Medicare Part D plans cover Rybelsus for type 2 diabetes with prior authorization. Coverage for weight loss is rare because it's not FDA-approved for that indication. Patients without coverage pay $900 to $1,000 per month.

Can you take Rybelsus if you don't have diabetes? Rybelsus is only approved for type 2 diabetes. Prescribing it to patients without diabetes is off-label, not supported by clinical trial data, and almost never covered by insurance. The safety and efficacy profile in non-diabetic populations is not established.

What are the side effects of Rybelsus? The most common side effects are nausea (11% to 20%), diarrhea (8% to 11%), and vomiting (5% to 9%). Most GI symptoms occur during dose escalation and resolve within 4 to 8 weeks. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (seen in rodents, unclear human risk).

How long does it take for Rybelsus to work? Blood sugar improvements typically appear within 2 to 4 weeks. Maximum A1C reduction occurs after 12 to 16 weeks at a stable dose. Weight loss, when it occurs, is gradual over months. The medication requires consistent daily dosing to maintain effect.

Can you switch from Ozempic to Rybelsus? Yes, but expect different results. Ozempic delivers higher semaglutide exposure, so switching to Rybelsus may result in less glycemic control and less weight loss. The switch is usually made for patient preference (avoiding injections) rather than clinical superiority. Discuss dose equivalency with your provider.

Is Rybelsus safer than injectable semaglutide? The safety profile is similar because both contain semaglutide. Rybelsus has slightly lower rates of nausea and vomiting in trials, likely because the maximum dose delivers less systemic drug exposure. The thyroid tumor warning, pancreatitis risk, and gallbladder risk apply to both formulations.

Does Rybelsus cause thyroid cancer? Semaglutide caused thyroid C-cell tumors in rodent studies at exposures similar to human therapeutic doses. The relevance to humans is unknown; no cases of medullary thyroid carcinoma were reported in clinical trials. Rybelsus carries a black box warning and should not be used in patients with personal or family history of medullary thyroid cancer or MEN 2.

Can you drink coffee after taking Rybelsus? Not immediately. Coffee reduces Rybelsus absorption by up to 73%. You must wait at least 30 minutes after taking Rybelsus before drinking coffee or any beverage other than water. Longer wait times (60 to 90 minutes) may improve absorption further.

What happens if you take Rybelsus with food? Food reduces semaglutide absorption by approximately 69%, making the dose largely ineffective. If you accidentally take Rybelsus with food, the medication will not work properly that day. Resume the correct dosing protocol the next morning. Do not take an extra dose to compensate.

Sources

1. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics. 2019.
4. Husain M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Circulation. 2019.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
6. Mosenzon O et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. 2019.
7. Pieber TR et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. 2019.
8. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019.
9. Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019.
10. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019.
11. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
12. Yamada Y et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. The Lancet Diabetes & Endocrinology. 2020.
13. Zinman B et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.